

Regulatory Affairs II Team, Division of Corporate Development 107, Ihyeon-ro30beon-gil, Giheung-gu Yongin-si, Gyeonggi-do, Korea

## **Declaration** letter

Dear Sir/Madame who might be concerned,

24 Jan 2025

We, GC Biopharma Corp., hereby declare that the 2025-2026 Northern Hemisphere strains which will be recommended by WHO for the composition of influenza virus vaccine for use in the 2025-2026 Northern Hemisphere influenza season, will be used for the production of GCFLU Quadrivalent Pre-filled syringe inj. in 2025-2026 NH.

The applied CPP can be issued by July 2025, from the Ministry of Food and Drug Safety (MFDS) after strain change approval in Republic of Korea.

Sincerely,

Younchul Shin
GC Blopharma Corp.

The document contains confidential and proprietary information. It should not be copied or disclosed to any third party without the written permission of GC Biopharma Corp.. The document shall be used for registration/regulatory purpose only and must be reviewed and approved with correspondent date and signature prior to release.